Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Clinical Chemistry
Emerging Technology
Immunoassays
Molecular Diagnostics
Pathology & AI
Molecular Diagnostics: Page 3
Blood test for Alzheimer’s shows high accuracy in study
By
Matt Limb
Scientists have hailed study results showing the high accuracy of a blood test that “could revolutionize” diagnosis of Alzheimer’s disease.
January 31, 2024
Jury awards Natera $96.3M in patent infringement case against CareDX
By
LabPulse.com staff writers
A jury in the U.S. District Court for the District of Delaware has ruled in favor of Natera in its patent infringement case against CareDx, awarding the firm approximately $96.3 million in damages in a unanimous verdict.
January 29, 2024
Researchers ID potential predictive biomarkers for CVD in type 2 diabetes
By
LabPulse.com staff writers
An analysis conducted by an international research team has identified 13 biomarkers that may improve the accuracy of predicting risk of cardiovascular disease (CVD) in people with type 2 diabetes.
January 25, 2024
Precision medicine at tipping point with looming FDA LDT oversight
By
Liz Carey
FDA targets companion diagnostics (CDx) LDTs first. In addition, CAP and AdvaMedDx set clear expectations, and what to know about the FDA-CMS joint statement on FDA oversight.
January 25, 2024
Sensorion receives clinical trial approval for congenital deafness gene therapy
By
LabPulse.com staff writers
French biotech firm Sensorion has received approval to initiate a phase I and II clinical trial in France of SENS-501 (the OTOF-GT program), its gene therapy for gene-mediated hearing impairment.
January 22, 2024
Study uncovers role of genetic variants in blood cancer development
By
Matt Limb
Scientists have used large scale data analysis to investigate why only some people with a common mutation go on to develop rare blood cancer.
January 23, 2024
First FDA-approved CRISPR-based gene therapy cleared for 2nd indication
By
LabPulse.com staff writers
A month after the U.S. Food and Drug Administration (FDA) approved Vertex Pharmaceuticals’ and CRISPR Therapeutics’ Casgevy for the treatment of sickle cell disease, the agency has given it a second U.S. regulatory approval ahead of schedule.
January 17, 2024
Weill Cornell study may support new prognostic test for prostate tumor spread
By
LabPulse.com staff writers
Scientists working in the department of pathology and laboratory medicine at Weill Cornell Medicine have found that certain noncancerous cells may be useful for assessing prostate tumors and their potential to spread.
January 16, 2024
Genevant Sciences forges $114M deal with Tome Biosciences on liver disease gene therapy
By
LabPulse.com staff writers
Biotech firm Genevant Sciences will collaborate with biotech startup Tome Biosciences on an in vivo gene editing treatment for a rare liver disorder.
January 16, 2024
IGI, Danaher launch CRISPR gene therapy research center
By
LabPulse.com staff writers
Danaher and the Innovative Genomics Institute (IGI) have launched a collaborative research center aimed at developing CRISPR-based gene therapies for a wide array of diseases.
January 12, 2024
Gene therapy, companion diagnostic hit milestones for hemophilia A
By
Liz Carey
Six months after the FDA approved a one-time gene therapy for severe hemophilia A reportedly priced around $2.5 million per patient, the Center for Inherited Blood Disorders, a 340B treatment center in California, has announced the drug's first infusion.
January 11, 2024
Tome Biosciences acquires Replace Therapeutics in $65M deal
By
LabPulse.com staff writers
Less than a month after Tome Biosciences emerged with $213 million in funding, the gene editing company will acquire Replace Therapeutics for $65 million in upfront and near-term milestones, with a total deal value of up to $185 million.
January 5, 2024
Previous Page
Page 3 of 193
Next Page